AUG 03, 2020 1:56 PM PDT

Improving Diagnostics in Breast Cancer

WRITTEN BY: Jasper Cantrell

Diagnostics is one of the essential tools in a physician’s toolkit. A good diagnostic test can identify whether a patient has a disease, the severity of the disease, and what treatments might work best for that patient.

Breast cancer represents a perfect example of how effective diagnostics can be. Most breast cancers fall under HER2+, ER+, or PR+ subtypes.  Each can be diagnosed using a test and come with tailored treatments. These tests are usually immunohistochemistry assays. These assays stain for a particular protein and score the patient based on how much of said protein is there have been extremely useful in recent decades. A group from Qingdao University in affiliation with Quanticision Diagnostics developed a new assay that might be even more effective.  The quantum dot blot.

Their quantum dot blot uses a special nitrocellulose plate in the test instead of the standard plate normally used. Nitrocellulose binds proteins better than the standard plates. They would also utilize fluorescence instead of standard staining, which would speed up the analysis portion of the test. Both of these combined would make a faster test that needed less of the patient’s sample.

In this study, they intended to validate the quantum dot blot by comparing it to the available immunohistochemistry tests. They developed a simple protocol similar to immunohistochemical tests and used HER2+ or HER2- patients as the test group. The quantum dot blot identified HER2+ samples just as well as immunohistochemistry testing. Using a “gold standard” method called FISH, they further validated that the QDB test could identify HER2+ samples with just as much accuracy as current testing methods.

Not to waste an opportunity, the team decided to analyze HER2+ test results, and identify any correlations. They found that grade three patients were five-fold more likely to have a HER2+ tumor than grade one. This may be due to lapses in treatment, as HER2+ therapies are relatively standard nowadays, but the team did not elaborate on their findings.

The study states, “To the best of our knowledge, this is the first time protein biomarker was measured absolutely and quantitatively in FFPE samples using an immunoassay.” Improvements to the methodology are a hallmark of science and help improve testing in labs and the hospital. The quantum dot blot test outlined in this study decreases the amount of patient sample needed and speeds up the process. The fluorescent reporter also makes quantitative, rather than qualitative results, which can reduce bias from doctors or lab technicians.

All-in-all, this study shows the quantum dot blot improves upon current immunohistochemical diagnostic tests. New tests like this often experience a slow implementation, as they sometimes need non-standard reagents and intensive validation. Still, with any luck, it can make the diagnosis of HER2+ breast cancer and other diseases more efficient.

Sources: Nature Scientific Reports, Vector Laboratories Inc
 

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
MAY 20, 2021
Clinical & Molecular DX
Ovarian Cancer Screening More Beneficial for Early Cancer Detection
MAY 20, 2021
Ovarian Cancer Screening More Beneficial for Early Cancer Detection
A UK-based research study has shown that while ovarian cancer screening is beneficial for detecting cancers earlier, it ...
JUN 15, 2021
Cancer
Red seaweed consumption is associated with a low risk of colon cancer - but why?
JUN 15, 2021
Red seaweed consumption is associated with a low risk of colon cancer - but why?
New research published in Marine Drugs explains why diets high in red seaweed are associated with a low risk of col ...
JUL 08, 2021
Cancer
Activating p53 May Boost Efficacy of Cancer Immunotherapy
JUL 08, 2021
Activating p53 May Boost Efficacy of Cancer Immunotherapy
Pharmacological activation of the p53 protein in cancer cells leads to an anti-tumor immune response in lab tests. These ...
JUL 16, 2021
Cancer
Exercise Slows Growth of Bowel Cancer Cells
JUL 16, 2021
Exercise Slows Growth of Bowel Cancer Cells
Exercise releases molecules into the bloodstream that reduce the growth of bowel cancer cells, say researchers from the ...
AUG 29, 2021
Cancer
Blood Test over 90% Accurate in Detecting Lung Cancer
AUG 29, 2021
Blood Test over 90% Accurate in Detecting Lung Cancer
An AI-powered blood test was able to correctly detect the presence of lung cancer over 90% of the time in patient sample ...
SEP 21, 2021
Drug Discovery & Development
Lifesaving TheraSpheres - glass microbeads can target and destroy colorectal tumors
SEP 21, 2021
Lifesaving TheraSpheres - glass microbeads can target and destroy colorectal tumors
The innovative medical device manufacturer Boston Scientific recently showed success in treating patients with ...
Loading Comments...